Lilly Alzheimer’s drug seen effective by FDA advisory panel

Eli Lilly &Co.’s drug for Alzheimer’s has benefits that outweigh its risks, U.S. drug regulatory advisers said, bringing the treatment’s long path to the market closer to a successful end. Eleven advisers to the Food and Drug Administration voted unanimously on Monday that Lilly’s donanemab helps patients in the early stages of Alzheimer’s disease, and that those benefits outweight the drug’s risks. The FDA is expected to make a final decision on donanemab by the end of the year. Lilly shares rose 1.8% at the 4 p.m. close of trading in New York.

Rhamondre Stevenson likely next up for a contract extension with the Patriots

FOXBORO, Mass. — Rhamondre Stevenson watched the New England Patriots’ offseason moves from afar, not saying much publicly as the team prioritized re-signing its homegrown talent. He watched the team ink new deals with Joshua Uche, Hunter Henry, Mike Onwenu, Kyle Dugger, Christian Barmore and Anfernee Jennings, a clear shift in thinking with a new front office that wants to reward successful players — many of them drafted by the team — with extensions. The thinking is that will help motivate others.